- Home
- AKTX vs YFOR Comparison
AKTX vs YFOR Comparison
Compare AKTX & YFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKTX | YFOR |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4M | 18.4M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AKTX | YFOR |
|---|---|---|
| Price | $8.54 | $1.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.50 | N/A |
| AVG Volume (30 Days) | 55.0K | ★ 291.2K |
| Earning Date | 11-12-2026 | 09-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.83 |
| Revenue Next Year | N/A | $31.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.99 |
| 52 Week High | $29.32 | $2.05 |
Technical Indicators
Market Signals| Indicator | AKTX | YFOR |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 37.62 |
| Support Level | $6.51 | N/A |
| Resistance Level | $10.98 | $1.55 |
| Average True Range (ATR) | 0.98 | 0.12 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 11.28 | 5.42 |
Price Performance
Historical ComparisonAbout AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.